1. A structural change in the global pharmaceutical marketplace.
- Author
-
Tempest, Brian
- Subjects
- *
INTERNATIONAL business enterprises , *STRATEGIC planning , *INDUSTRIAL productivity , *INDUSTRIAL management , *PHARMACEUTICAL industry - Abstract
Asia is becoming a centre of gravity for global business. As a result of this, there is a growing interest in investment in this area, and pharmaceutical companies are not an exception. The old research and development investment model of the Western Big Pharma companies is starting to fall apart with the well-publicised reduction of new chemical entities productivity. Big Pharma is rethinking its business opportunities. Today, 88 per cent of the world's pharmaceuticals are shared between only 18 per cent of the world's population, which means that 82 per cent of the world's population has access to only 12 per cent of the world's pharmaceuticals. This presents a unique business opportunity for those that can seize the moment. Within this context, we are witnessing the use of different strategies by pharmaceutical companies. Some Big Pharma companies have a generic strategy, some have a developing world strategy, some have an outsource strategy and others have all three. The current mergers and acquisitions of pharmaceutical companies in India portray these structural profound changes. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF